SRP3144

PLGF-3 human

≥95% (SDS-PAGE & HPLC), recombinant, expressed in E. coli, lyophilized, suitable for cell culture

• Synonym(s): PGFL, Placenta Growth Factor-3
• UNSPSC Code: 12352202
• NACRES: NA.32

Properties

• product name: PLGF-3 human, recombinant, expressed in E. coli, ≥95% (SDS-PAGE), ≥95% (HPLC), suitable for cell culture
• biological source: human
• recombinant: expressed in E. coli
• assay: ≥95% (HPLC); ≥95% (SDS-PAGE)
• form: lyophilized
• potency: 5.0-50.0 ng/mL
• mol wt: 45.7 kDa
• packaging: pkg of 25 μg
• technique(s): cell culture | mammalian: suitable
• impurities: <0.1 EU/μg endotoxin, tested
• color: white
• UniProt accession no.: P49763
• shipped in: wet ice
• storage temp.: −20°C
• Gene Information: human ... PGF(5228)

Description

General description

PLGF (placental growth factor), originally identified in human placenta, is a member of the VEGF (vascular endothelial growth factor) family. This protein is predominantly expressed in placenta, and also shows expression in heart, thyroid, lung and skeletal muscle. It is alternatively spliced to produce four isoforms in humans namely, PLGF1, PLGF2, PLGF3 and PLGF4. PLGF gene is localized to human chromosome 14q24, spans 800kb and is composed of seven exons.
Recombinant human PlGF-3 is a 45.7kDa disulfide-linked homodimeric protein of two 203 amino acid polypeptide chains.

Biochem/physiol Actions

PLGF (placental growth factor) is involved in angiogenesis, but does not play an essential role in angiogenesis during reproduction and development. However, inactivation of this gene in pathological conditions such as, ischemia, inflammation and cancer, results in impaired angiogenesis. Preclinical studies show that this protein might be a therapeutic target for treatment of angiogenesis and inflammation related disorders. In acute coronary syndrome (ACS) patients, increased levels of PLGF are linked with obstructive sleep apnea (OSA) and short-term adverse outcomes.

Sequence

LPAVPPQQWA LSAGNGSSEV EVVPFQEVWG RSYCRALERL VDVVSEYPSE VEHMFSPSCV SLLRCTGCCG DENLHCVPVE TANVTMQLLK IRSGDRPSYV ELTFSQHVRC ECRHSPGRQS PDMPGDFRAD APSFLPPRRS LPMLFRMEWG CALTGSQSAV WPSSPVPEEI PRMHPGRNGK KQQRKPLREK MKPERCGDAV PRR

Physical form

Lyophilized with no additives.

Reconstitution

Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.

Safety Information

• Storage Class: 11 - Combustible Solids
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable